146 related articles for article (PubMed ID: 37094238)
1. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
García-Lezama M; Carrillo-Ruiz JD; Moreno-Jiménez S; Roldán-Valadez E
Gac Med Mex; 2023; 159(2):161-168. PubMed ID: 37094238
[TBL] [Abstract][Full Text] [Related]
2. Updates on the WHO diagnosis of IDH-mutant glioma.
Reuss DE
J Neurooncol; 2023 May; 162(3):461-469. PubMed ID: 36717507
[TBL] [Abstract][Full Text] [Related]
3. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
4. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
[TBL] [Abstract][Full Text] [Related]
5. Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.
Zakharova G; Efimov V; Raevskiy M; Rumiantsev P; Gudkov A; Belogurova-Ovchinnikova O; Sorokin M; Buzdin A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613601
[TBL] [Abstract][Full Text] [Related]
6. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
[TBL] [Abstract][Full Text] [Related]
7. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Pinarbasi E; Camelo-Piragua S; Capizzano AA; Liao E; Srinivasan A; Moritani T
Radiographics; 2022; 42(5):1474-1493. PubMed ID: 35802502
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis.
Li Y; Qin Q; Zhang Y; Cao Y
Curr Oncol; 2022 Sep; 29(10):6893-6907. PubMed ID: 36290819
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
10. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
11. IDH1 and IDH2 mutations in gliomas.
Cohen AL; Holmen SL; Colman H
Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
[TBL] [Abstract][Full Text] [Related]
12. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
13. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
14. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
16. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the occurrence rates of
Cho U; Yang SH; Yoo C
J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
[TBL] [Abstract][Full Text] [Related]
19. [World Health Organization Classification of Central Nervous System Tumours, 5
Ichimura K
No Shinkei Geka; 2023 Mar; 51(2):349-363. PubMed ID: 37055056
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
